New Research Reports

Cipla has secured its much awaited USFDA approval of gAbraxane following Change in Estimates | Target | Reco the Goa facility clearance in November 2024, milestone that reinforces our positive stance on the company. Our FY26E and FY27E EPS factors in...

Deal wins remain strong, above USD 10 bn for 2nd successive quarter The revenue growth in Q4 was disappointing, missing our estimates by 90bps QoQ, largely attributed to the ramp down in BSNL deal. Otherwise, the international business grew 0.6% QoQ, curtesy BFSI (+1.3% QoQ) and other key geographies that sequentially turned positive after a weak growth reported in Q3. The deal TCV at USD12.2bn (+20% QoQ), was impressive with no major change in the mix or nature of the deals. The management was confident of deriving growth in the international market on the back of strong bookings in...

Weak start for FY26 likely. Salary hike postponed due to uncertainty in the demand environment

TCS reported revenue of USD7.5b in 4QFY25, down 1.0% QoQ in USD terms vs. our estimated decline of 0.8%. FY25 revenue stood at USD30.2b, up 4.2% YoY in CC.

Tata Steel (TSL) has embarked on a major transformation plan at Tata Steel Netherlands (TSN) – built on a multi-pronged approach to maximise production efficiencies, lower fixed costs, optimise product mix and margins.

TCS Q4FY25 reported revneue stood at $7,465 million, down 1% q-o-q/up 1.4% y-o-y, missing our estimate of $7,501 million. Revenue growth in constant currency (CC) terms stood at 2.5% y-o-y. Revenue in rupee terms stood at Rs. 64,479 crore, up 0.8% q-o-q/5.3% y-o-y.

The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24.

Indian Hotels’ (IH) transformational journey over the past decade is marked by bold strategic moves—embracing an asset-light model, reimagining Ginger Hotels, and expanding into new segments.